<DOC>
	<DOCNO>NCT00994851</DOCNO>
	<brief_summary>Primary Objective : To evaluate clinical efficacy Naturetti ( capsule ) , consider follow criterion : - Evacuation frequency treatment follow-up period - Consistency stools treatment follow-up period - Global evaluation , regard increase frequency evacuation shape stool . Secondary Objective : - Number day without evacuation - Proportion evacuation pain - Proportion evacuation strain - Proportion evacuation incomplete sensation - Proportion block stool - Proportion manual maneuver facilitate defecation - Proportion subject adhere diet recommended - Proportion patient use rescue medication - Level constipation improvement , accord patient evaluation - To evaluate clinical tolerability study medication continuous use - To evaluate occurrence adverse event relate study drug - To identify drug interaction .</brief_summary>
	<brief_title>Evaluation Cassia Fistula + Senna Alexandrina Miller Chronic Functional Constipation Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Senna Extract</mesh_term>
	<mesh_term>Sennoside A &amp; B</mesh_term>
	<criteria>Inclusion criterion : Chronic functional constipation present , diagnose Rome III criterion . Present evacuation intestinal feces classify Type 1 2 classification Bristol . Women sexually active reproductive age , use three month effective contraceptive method . Concordance , level education consciousness enough cooperate completion study procedure . No contraindication use medication study . Availability attend visit study evaluation . Exclusion criterion : History presence neurological disorder / metabolism . Persons constipation cause previous surgery . Presence obstructive lesion gastrointestinal tract , include colorectal cancer . Irritable bowel syndrome inflammatory bowel disease . Multiple Sclerosis Parkinson 's disease Other abnormalities Hirschsprung 's disease Defecation Dissinrgica . Heart disease / hypertension . Continuous use medication analgesic , anticholinergic ( antihistamine , antispasmodic , antidepressant , antipsychotic ) , supplement iron aluminum , Opiates , Antihypertensive , CALCIUM CHANNEL BLOCKERS Preganglionic blocker . Use except laxative rescue medication study . Subjects confirm diagnosis ICFC Phase I study . Pregnant breastfeeding period . Laboratory test outside normal range , result assess clinically significant Investigator . Body Mass Index ( BMI ) 30 . Participation another clinical study within 30 day . Do fill correct Diary Any condition view researcher impossible Subject participate study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>